ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by jordon3on Mar 28, 2018 11:10pm

183 Views

Post# 27799933

RE:RE:RE:Dedfinat Indication that PMN is setting up for clinicals

RC why are you so convinced PMN will never reach the clinical stage? Just asking what would persuade you to believe this? Hope you are correct. Frankly with what PMN has...one would think a buyout would be soon rather than later. Some of these big Pharma companies are worth tens of billions. A buyout of $50 a share is a drop in the bucket.......

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?